Hosenkoside A has shown significant potential in anti-inflammatory applications. It works by inhibiting key inflammatory mediators such as nitric oxide and prostaglandin E2, making it a candidate for development in treatments targeting chronic inflammatory conditions. Studies indicate it suppresses the activation of NF-κB, a critical signaling pathway involved in inflammation and immune response. Due to this mechanism, Hosenkoside A is being explored for use in pharmaceuticals aimed at managing diseases like arthritis, inflammatory bowel disease, and other immune-related disorders. Additionally, it exhibits antioxidant properties, which may contribute to its protective effects in cellular models of oxidative stress. Research is ongoing to evaluate its bioavailability and therapeutic efficacy in vivo.